Record of Decisions - November 18, 2009 - Canadian Consumer Specialty Products Association (CCSPA)

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Contact: Office of Business Transformation

Health Canada - Health Products and Food Branch - Bilateral Meeting Program

Record of Decisions: Canadian Consumer Specialty Products Association (CCSPA)

Location: 1600 Scott Street, Holland Cross, Tower B, 2^nd Floor, Boardroom 2048, Ottawa, Ontario

Date: Wednesday, November 18^th, 2009

Start Time: 1:30 p.m.

End Time: 3:10 p.m.

Participants

CCSPA Participants

Shannon Coombs, President, CCSPA, Co-Chair

Stephen Chambers, Dell Tech Laboratories

Mike Gilbrook, SC Johnson and Son, Ltd.

Rhonda Jones, Scientific and Regulatory Consultants

Catherine Ujihara, Clorox

Jan Wengler, Reckitt Benckiser

Via Teleconference:

Karinne Chan, Proctor and Gamble

Cheryl Fougere, Director of Policy, CCSPA

Melissa Klamerus, Ecolab

Brenda Watson, Clorox

Jim Wiersig, Clorox

Health Canada Participants

Supriya Sharma, Director General, Therapeutic Products Directorate (TPD), Co-Chair

Barbara J Sabourin, Senior Executive Director, TPD

Jacques Bouchard, Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD), TPD

Yadvinder Bhuller, BGIVD, TPD

Gail Gervais, Liaison Unit, Office of Business Transformation (OBT), TPD

Karin Hay, Bureau of Policy, Science and International Programs (BPSIP), TPD

Holly Hutchings, Policy, Planning and International Affairs Directorate (PPIAD)

Lisa Lange, BPSIP, TPD

Denise Quesnel, Liaison Unit, OBT, TPD

Shannon C. Wright, BGIVD, TPD

Brigitte Zirger, BPSIP, TPD

Observers

Brian Parker, OBT, TPD

Hieu Vu, OBT, TPD

1. Welcome and Introductions

Dr. Supriya Sharma, Director General, TPD, welcomed everyone, and a roundtable of introductions followed.

Dr. Sharma mentioned that in terms of human resources, there were no major changes to report and that the organization was stable.  TPD has been busy with the H1N1 and other files.

2. Review of Agenda

Approved

3. Approval of the Meeting Notes of May 20^th, 2009

Approved.

The follow-up items from the previous meeting will be addressed on this agenda.

4. Review of the Guidance Document

Shannon C. Wright, Assessment Officer, Disinfectants Unit, BGIVD, TPD, responded to this issue by informing CCSPA that TPD has drafted a set of Frequently Asked Questions (FAQs) to which CCSPA has already provided the relevant input. The revisions are now complete and the FAQs will now proceed via the approval process, starting with Director level approval.  It is anticipated that with the current environment, delays in having the document posted to the Health Canada Web site could arise.  Therefore, following a successful approval process, TPD will consider other options as needed for getting this information to all stakeholders.

Shannon Coombs, CCSPA, questioned the process for removing products from the Guidance document based on the outcome of the chemical management plan.  Brigitte Zirger, Director, BPSIP, explained that staff from BPSIP sits on the working group and during the assessment, some products have been identified as environmental or toxic to human health.  In turn, the results of this assessment are relayed to the relevant bureau, such as BGIVD.

CCSPA requested an update regarding the possibility for having training sessions sponsored and arranged by CCSPA.  In response, TPD indicated that they recognize the potential benefits of holding a training session for sponsors on submission requirements.  However, resources would have to be shifted from review activities in order to prepare and participate in such training.  Given the current limited resources, it is not likely that such training could occur within this fiscal year.

5. Joint Reviews between TPD and Pest Management Regulatory Agency (PMRA)

Jan Wengler, Reckitt Benckiser, CCSPA, asked if TPD was having joint reviews with PMRA. Dr. Sharma clarified that TPD was not working with PMRA on any joint reviews of disinfectants and sanitizers.

Holly Hutchings, Analyst, Strategic Horizontal Policy Division of the Policy, Planning and International Affairs Directorate (PPIAD), provided an update regarding the meeting that occurred to discuss the overall regulatory framework that governs these types of products with Healthy Environments and Consumer Safety (HECS) and PMRA.

Stephen Chambers, Dell Tech Laboratories, Rx&D, discussed the possibility of a dual jurisdiction label and CCSPA agreed to provide specific examples of such labels.

Action:  CCSPA will provide specific examples of dual labels.  PPIAD to report at the next meeting how the internal working group is progressing.

6. H1N1 / Emerging Pathogens

Yadvinder Bhuller, BGIVD, TPD, indicated that TPD has accepted CCSPA's comments as they added clarity to the Notice. The document is being finalized and will then be sent for posting.

Dr. Supriya Sharma indicated that Health Canada will make additional changes to the Notice, based on the discussion, in order to further clarify the relevant sections of the Notice.

Shannon Coombs thanked TPD for the work done on the Notification and she will be informing CCSPA's members.

7. Roundtable

a) Natural Claims
Mike Gilbrook, SC Johnson and Son, Ltd., CCSPA, asked if Health Canada had received any claims on 'green products'.  Dr. Sharma mentioned that she was not aware of any such claims.

8. Adjournment

Meeting adjourned at 3:10 p.m.

9. Next meeting:

Wednesday, May 26^th, 2010 at 1:30 p.m.

Original signed by

Dr. Supriya Sharma
Director General
Therapeutic Products Directorate